What is it about?
This work details the engineering of an exogenous contrast agent platform composed of FDA-approved dye that can be easily synthesized and functionalized with targeting molecules has tunable sizes, and has maximum optical absorption in the near-infrared region. This allows imaging of deep tissues with greater contrast.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
By 2050, cancer is projected to be the biggest pandemic ailing the world. One of the ways to improve patient outcomes and their five-year prognosis is through early diagnosis of tumors. Our biocompatible contrast agent equips healthcare professionals with the ability to image deep tumors in real-time, and conduct biopsies and sentinel lymph node imaging to determine the extent of metastasis using photoacoustic imaging.
Perspectives
The easy synthesis, size-tuning, and targeting properties of the platform make this a great industrial manufacturing product.
Dr. Shrishti Singh
George Mason University
Read the Original
This page is a summary of: Size-tunable ICG-based contrast agent platform for targeted near-infrared photoacoustic imaging, September 2022, Cold Spring Harbor Laboratory Press,
DOI: 10.1101/2022.09.01.506234.
You can read the full text:
Resources
Contributors
The following have contributed to this page
